Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04981678 · ClinicalTrials.gov registry record · Phase 4
The Effect of Buprenorphine Continuation for Patients With Opioid Use Disorder
A Phase 4 study, sponsored by MaineHealth.
- Terminated
- Registry status
- Phase 4
- Development phase
- 12
- Enrollment target
NCT04981678 is a Phase 4 study that was terminated before completion, run by MaineHealth. The registered enrollment target is 12 participants.
The verdict
NCT04981678, a Phase 4 study, was terminated before completion, sponsored by MaineHealth.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 12 participants
- Enrollment target
Study Summary
There is limited guidance on the optimal management of buprenorphine perioperatively and both buprenorphine discontinuation and continuation are acceptable standards of care. Buprenorphine continuation at low analgesic dosing is also accepted, however is not provided as a potential treatment strategy by the Substance Abuse and Mental Health Services Administration (SAMHSA). There is the risk of inadequate pain control necessitating opioid escalation when buprenorphine is continued. Preliminary clinical observations support buprenorphine continuation at low analgesic doses (8mg) as it adequately facilitates postoperative pain management without interrupting opioid use disorder (OUD) treatment, however to date, no prospective trial has investigated this treatment strategy in comparison to full dose buprenorphine continuation. Since optimal perioperative dosing strategies remain unknown, the purpose of this study is to investigate if buprenorphine continuation at analgesic dosing is superior to full dose buprenorphine continuation in individuals presenting for elective surgery.
Interventions
- DRUG Buprenorphine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2022-01-01 |
| Est. Completion | 2023-10-16 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04981678
The ClinicalTrials.gov registry entry for NCT04981678 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MaineHealth, which has 26 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Buprenorphine is the first listed.
NCT04981678 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04981678 about?
NCT04981678 is a clinical study titled "The Effect of Buprenorphine Continuation for Patients With Opioid Use Disorder". There is limited guidance on the optimal management of buprenorphine perioperatively and both buprenorphine discontinuation and continuation are acceptable standards of care. Buprenorphine continuation at low analgesic dosing is also accepted, however is not provided as a potential treatment strateg...
What is the current status of trial NCT04981678?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 12 participants. The study started on 2022-01-01. Estimated completion is 2023-10-16.
What interventions are being tested in trial NCT04981678?
The interventions under investigation include: Buprenorphine (DRUG).
Who is sponsoring clinical trial NCT04981678?
This trial is sponsored by MaineHealth, which has 26 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.